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Objective: To analyze the correlation between the pharmacotherapy response and the characteristics of the
pre-treatment regional cerebral blood flow (rCBF) in patients with obsessive-compulsive disorder (OCD).
Methods: Single-photon emission-computed tomography (SPECT) was used to determine the pre-treatment rCBF in
30 OCD patients and 30 normal controls. Based on their clinical remission response, the subjects were divided into
two groups: selective serotonin reuptake inhibitors (SSRIs) and SSRIs plus quetiapine. The subjects with clinical
remission response were identified after treatment for a period of 24 weeks, and the rCBF imaging data were
processed using statistical parametric mapping (SPM) software with two-sample Z-tests.
Results: Nineteen OCD patients who achieved clinical remission were included in the study. Increased rCBF in forebrain
regions, including the frontal lobe, cingulate gyrus, hypothalamus, and basal ganglia, was found in 11 responders to
SSRIs compared to normal control patients. The eight SSRI plus quetiapine responders exhibited a decrease in rCBF
within posterior brain regions, including the parietal lobe, cerebellar vermis, and occipital lobe, and an increase in rCBF
in the frontal lobe, thalamus, basal ganglia, and cerebellum tonsil compared to normal control patients.
Conclusions: The characteristics of increased rCBF in forebrain regions and decreased rCBF in posterior brain regions
before treatment of OCD patients was a potentially predictor of treatment response to guide treatment options.
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Functional imaging studies using positron emission tomog-
raphy (PET), functional and structural magnetic resonance
imaging (fMRI), and single-photon emission tomography
(SPECT) techniques have indicated that the pathophysi-
ology of obsessive–compulsive disorder (OCD) involves
widely distributed, large-scale brain systems including the
orbitofrontal cortex (OFC), the anterior cingulate cortex
(ACC), the dorsolateral prefrontal cortex (DLPC), the head
of the caudate nucleus, and the thalamus [1-3]. The im-
aging of regional cerebral blood flow (rCBF) using SPECT
is also a useful tool for studying OCD, as changes in rCBF
generally accompany cerebral dysfunction. Functional im-
aging studies using SPECT techniques have revealed both* Correspondence: wenshl@mail.sysu.edu.cn
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reproduction in any medium, provided the orincreased and decreased rCBF in various brain regions, in-
cluding the basal ganglia, cingulate cortex, orbitofrontal
cortex, and anterior cingulate, in patients with OCD com-
pared to normal controls [4-6]. Some researchers sug-
gested that the changes in spontaneous neuronal activity
within posterior brain regions, including the inferior par-
ietal cortex, occipital lobe and cerebellum, played an im-
portant role in the pathophysiology in patients with OCD
[3,7]. In a SPECT study, Busatto [6] also reported that the
rCBF within the cerebellum was greater in patients with
OCD compared to healthy control subjects. These studies
proposed that a dysfunction in forebrain and/or posterior
brain regions would result in the emergence and main-
tenance of repetitive thoughts and characteristic OCD-
like behavior.
Selective serotonin reuptake inhibitors (SSRIs) have
proven effective for the treatment of OCD in a number
of open and controlled trials [8,9]. Several functionald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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treatments using either SSRIs or behavioral therapy sug-
gested that the activity in the OFC, ACC, DLPC, thal-
amus, and caudate nucleus was decreased by successful
treatments [10-12]. Although SSRIs are effective in treating
OCD patients, 40%–60% of patients do not show an ad-
equate response to these medications [13,14].
In clinical practice, the addition of a low-dose, atypical
antipsychotic such as risperidone or quetiapine to on-
going SSRI treatment has been shown to be effective
[15,16]. Sumitani [17] reported that OCD patients who
responded to an SSRI plus atypical antipsychotic showed
distinct biological abnormalities in the anterior cingu-
late. Buchsbaum [18] found that the successful treatment
with SSRIs plus risperidone of OCD patients who were
non-respondent to serotonin reuptake inhibitors alone
was associated with relatively low metabolic rates in the
striatum and anterior cingulate gyrus. Only one third of
treatment-refractory OCD patients show a meaningful
treatment response to antipsychotic augmentation [13].
Therefore, OCD patients who respond to different phar-
macotherapies would show differential changes in brain
perfusion in those regions affected by the treatment;
these studies suggest that the OCD is a highly heteroge-
neous condition. It is possible that there are biological
differences among OCD patients that create this special
subgroup that shows pharmacological response. On the
basis of previous studies, we proposed that abnormal ac-
tivation involving forebrain and posterior brain regions
might affect the interference processes that are associated
with the pathophysiology of OCD, and that a difference in
pre-treatment rCBF might predict the pharmacotherapy
response to different treatments.
To understand the underlying pathophysiology better
and analyze the correlation between the pharmacother-
apy response and the characteristics of the pre-treatment
rCBF, we believed that a comparison between remitted
OCD patients using different drugs (SSRIs or SSRIs plus
quetiapine) and healthy controls of the characteristics of
the rCBF changes would be potential clinical valuable.
The aim of this study was to summarize the characteris-
tics of rCBF before treatment occurring in OCD patients
who responded to SSRIs or SSRIs plus quetiapine using
the SPECT technique and SPM evaluation to guide the
option of clinical pharmacotherapy in OCD patients.
Materials and methods
Subjects
We recruited 30 untreated, first-episode patients with
OCD based on the DSM-IV criteria (American Psychiatric
Association, 1994), Yale-brown Scale (the Yale-brown
Obsessive-Compulsive Scale Y-BOCS) total score > 16
points, and HAMD (Hamilton Rating Scale for Depression,
24 item) total score <35. The results of cerebral EEGs werenormal. The subjects, who included 18 males and 12 fe-
males whose mean age was 27.13 ± 8.98 years, were from
in the in/out-patient clinic in the department of psychology
at the third hospital of Sun Yat-sen University. Thirty vol-
untary controls individually matched for age, sex, handed-
ness, level of education and intelligence quotient (IQ),
including 17 males and 13 females with a mean age of
29.3 ± 6.8 years, were free of neurological and psychiatric
disorders and without any history of OCD. All patients
were free of serious body or brain organic disease,
substance abuse, and other neurological or psychiatric dis-
orders including depression (HAMD score >35), schizo-
phrenia, bipolar disorder, tics or alcohol/substance abuse.
All participants gave written informed consent to partici-
pate in the study after the procedures were explained and
all recommendations of the local ethical committee (Third
Affiliated Hospital Of Sun Yat-sen University) were met.
The demographic and clinical data of the OCD patients
and healthy controls were shown in Table 1.
Regional cerebral blood flow (rCBF) imaging protocol
The rCBF imaging was performed using dual-head gamma
cameras (SPECT, Discovery VH, GE Healthcare, USA)
under resting conditions in quiet surroundings with the
subjects’ eyes covered for approximately 30 minutes after
each subject was injected with approximately 740 MBq
Tc-99 m ethylcysteinate dimer (Beijing atom high-tech
Co. Ltd, China). The 64 frames (40s per frame in a matrix
of 128 × 128 pixels) were acquired over a least radius orbit
with a dual-headed rotating camera equipped with low-
energy high-resolution parallel-hole collimators. The raw
data were pre-filtered with a Butterworth low pass filter
(Order 10, cutoff frequency 0.45 cycles/pixel) to minimize
noise and then reconstructed using a filtered back projec-
tion algorithm and Chang’s first-order post-processing at-
tenuation correction (0.13/cm as a routine attenuation
coefficient in the clinical setting) [3]. The reconstructed
data were transformed to DICOM 3.0 format files and
exported to a general workstation.
Pharmacotherapy and assessment instruments
Patients underwent treatment with selective serotonin
reuptake inhibitors (SSRIs) with or without the addition
of a low dose atypical anti-psychotic. The choice of SSRI
was based on the individual sex, age, clinical symptoms,
length of illness and side-effect history of each patient,
and the patients were scheduled to receive paroxetine,
fluvoxamine, sertraline, citalopram and fluoxetine ac-
cordingly. Patients were started on a low dose SSRI
(50 mg/day for fluvoxamine and sertraline, 20 mg/day for
fluoxetine, paroxetine and citalopram). The dosage of
SSRIs, if tolerated, was slowly increased to the maximum
recommended for OCD. The duration of the trial of treat-
ment was 24 weeks. Y-BOCS and HAMD assessments
Table 1 Demographic and clinical data for OCD patients and healthy controls
Variables Pre-treatment groups (case) Treatment remission groups (case)
OCD group (19) Controls (30) P SSRI (11) SSRI/quetiapine (8) P
sex (female, %) 9(47) 13(43) 0.214 5(45) 4(50) 0.305
age (years) 27.21 ± 8.75 29.25 ± 6.81 0.291 28.18 ± 8.2 26.78 ± 7.66 0.286
education (years) 12.66 ± 3.17 13.30 ± 2.47 0.667 12.12 ± 3.77 12.53 ± 3.13 0.797
length of illness (years) 2.47 ± 1.33 — 2.33 ± 1.99 2.97 ± 1.34 0.714
pre-treatment scales
Y-BOCS total score 24.55 ± 6.72 11.12 ± 5.12 0.013 24.36 ± 6.22 24.55 ± 7.41 0.731
HAMD total score 21.21 ± 4.36 16.33 ± 2.41 0.044 21.30 ± 4.11 21.00 ± 4.17 0.712
Post-treatment scales
Y-BOCS total score 12.48 ± 5.20 * — 11.51 ± 5.01 * 11.36 ± 5.14 * 0.512
HAMD total score 17.31 ± 3.49 * — 17.03 ± 3.18 * 17.21 ± 3.33 * 0.647
*p < 0.01, compared to the pre-treatment score.
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later follow-up assessments were performed. To ensure
that clinician-rated measures were consistent across pa-
tients and time-points, raters met regularly to review
the procedures and to discuss their experiences using
the measures.
The assessment of the clinical remission response
and groups
We adopted the following clinical criteria: a >50% reduction
in the Y-BOCS total scores for the clinical remission
of pharmacotherapy; a reduction of >25% and <50% in the
Y-BOCS total scores for the clinical response of pharmaco-
therapy; and a reduction of <25% in Y-BOCS total scores
for the clinical incomplete responses of pharmacotherapy at
the end of a 12-week treatment with a high-dose SSRI.
A recommended augmentation dose of quetiapine (200–
300 mg/day) was slowly added to the treatment in pa-
tients who had incomplete responses to SSRI treatment
at the end of 12 weeks of treatment with the maximum
tolerated doses. Of the 30 patients, eight dropped out
during follow-up visits because of a lack of response to
the treatment, and three patients dropped out because of
drug side effects. Finally, 19 OCD patients who achieved
a clinical remission (eleven patients responded to SSRI
treatment and eight patients responded to SSRIs plus
quetiapine) were included in the study. The results of this
study were based on the data from those 19 patients (ten
men, nine women) who completed the study and were
divided into SSRIs treatment and SSRIs plus quetiapine
treatment groups.
SPM analysis
All imaging data were converted to the analyzed format
using a freeware analysis viewer (MRIcro, version 1.40).
All DICOM data were processed with statistical paramet-
ric mapping (SPM 5) software (free downloaded fromhttp://www.filion.ucl.ac.uk/spm) running on MATLAB
6.5 (Mathworks Inc., Sherborn, MA). The image data
were spatially normalized into a standard stereotactic
space as defined by the atlas of Talairach and Tournoux
(Talairach and Tournoux, 1988). The normalized images
were smoothed with a 10-mm isotropic full-width, half-
maximum Gaussian kernel to account for inter-subject
differences in anatomy and to allow for valid statistical
inference according to Gaussian random field theory.
The rCBF images from the two OCD patient groups
and the controls were analyzed using the SPM software
and a two samples model. Correlation between the
rCBF and Y-BOCS score within the OCD group was
performed using a single subject and covariates-only
model in SPM analysis. The scores of Y-BOCS were en-
tered as covariates in the statistical analysis, which used
a general linear model, of each association. The rCBF
image was modelled using a covariance scaling of activ-
ity to a normal mean global activity of 50 ml/100 g/min.
For the general linear model, the estimated threshold
was set to P < 0.001 and a family-wise error (FWE) cor-
rection and a small-volume correction (sphere of radius
50 pixels) were used.
Statistical analysis
Statistical analysis was performed using SPSS version
17.0 for Windows. One-way analysis of variance (ANOVA)
and chi-squared statistics were used to determine the
statistical significance of age, sex, years of education,
length of illness, Y-BOCS and HAMD total score.
Results
Demographic and clinical data of OCD patients and
healthy controls
OCD patients who completed the study and the con-
trol group were not significantly different with re-
spect to sociodemographic characteristics (Table 1).
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between the OCD patients who completed the study and
those who dropped out with respect to age (p = 0.234),
gender (p = 0.534) and the length of illness (p = 0.325).
The clinical and demographic features of the SSRI
and the SSRI plus quetiapine groups were also sum-
marized in Table 1. No significant differences were
found between the two groups in terms of other clinical
characteristics. A 63.3% (19/30) patients who showed
improvement in obsessive-compulsive symptoms (com-
pared to the initial Y-BOCS scores) was observed in all
patients at 24 weeks. The Y-BOCS and HAMD scores
decreased significantly during the remission period
compared to pre-treatment (t = 5.63, p = 0.000; t = 6.11,
p = 0.000).
The rCBF of the SSRI group and normal controls before
treatment
The increased rCBF was found in SSRI group compared
to normal controls before treatment. The increased
rCBF regions primarily included the left lenticular nu-
cleus, left thalamic lateral nucleus, left medial frontal
gyrus, left anterior cingulate, right globus pallidus and
right thalamic lateral nucleus (Figure 1). The coordinates
and Z scores of the abnormal cerebral regions were shown
in Table 2.
The rCBF of the SSRI plus quetiapine group and normal
controls before treatment
The increased and decreased cerebral perfusion was
found in the SSRI plus quetiapine group. The regions of
decreased rCBF primarily included the left inferior par-
ietal lobule, left vermis cerebelli and right occipital wedge
leaf (Figure 2). The regions of increased rCBF primarily
included the left tonsil of the cerebellum, left globus
pallidus, right thalamoc lateral nucleus, right lentiformFigure 1 The image A was the most intensity projection image of t
The image B was the three dimensional image of rendered with increasnucleus, and right middle frontal gyrus (Figure 3). The
coordinates and Z scores of the abnormal cerebral re-
gions were shown in Table 3.
Correlation between the pre-treatment rCBF and change
in the Y-BOCS score
Correlation between the pre-treatment rCBF and change
in the Y-BOCS score Among SSRI group (n = 11), the
reduction in the Y-BOCS score was negatively corre-
lated with the pre-treatment rCBF in the left frontal
lobe, left cingulate and bilateral thalamus (P < 0.001,
FWE-corrected) . Among SSRI plus quetiapine group
(n = 8) the reduction in the Y-BOCS score was nega-
tively correlated with the pre-treatment rCBF in the
left and right frontal lobe, thalamus and left parietal lobe
(P < 0.001, FWE-corrected) and positively correlated with
left cerebelli and right occipital lobe (P < 0.001, FWE-
corrected). Those results suggest that an increased rCBF
in forebrain regions may predict a improvement in OCD
severity after SSRI treatment, and that an increased in
forebrain regions and a decreased in posterior brain re-
gions rCBF may predict a improvement in OCD severity
after SSRI plus quetiapine treatment.
Discussion
In our study, the increased rCBF was found in the SSRI
treatment group compared to normal controls before
treatment, and the area of increased rCBF primarily in-
cluded the left lenticular nucleus, left thalamic lateral
nucleus, left medial frontal gyrus, left anterior cingu-
late, right globus pallidus and right thalamic lateral nu-
cleus. These results suggest that only increased rCBF in
forebrain predicts response to SSRIs; similar findings were
reported previously in OCD patients [19,20]. Functional
imaging studies using SPECT techniques have proposed
that a dysfunction in these diffuse cortical networks wouldhe increased rCBF focuses in the patients with SSRI treatment.
ed rCBF focuses.
Table 2 The coordinates and Z scores of abnormal rCBF in SSRI group and normal controls before treatment
Hemisphere Brain region Coordinates(mm)a Z valueb P value
X Y Z
left lenticular nucleus −16 6 −8 5.64 0.000
left Thalamus lateral nucleus −26 −32 6 4.62 0.000
left Medial frontal gyrus −12 20 44 4.31 0.000
left Anterior cingulate −10 32 16 4.16 0.000
right Globus pallidus 24 −8 2 4.13 0.000
right Thalamus lateral nucleus 12 −6 0 4.03 0.000
a Coordinates from the stereotaxic atlas of Talairach and Tournoux.
b Peak activation in a cluster of at least 50 voxels in which the difference survived a threshold of P < 0.001 in a random-effects analysis.
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thoughts and characteristic OCD behavior. However, few
studies have investigated these brain imaging findings asso-
ciated with the clinical remission observed following the
use of SSRIs or SSRIs plus quetiapine in OCD patients.
In a previous SPECT study by Hendler [20], it was found
that, after six months of sertraline treatment, OCD pa-
tients responding to SSRIs showed increased activation in
the frontal cortex during both relaxing and symptom-
provoking conditions. The authors proposed that the
response to SSRIs may be related to the short-term plas-
ticity of cortical neurons. However, Rauch [21] used SPM
methods to investigate predictors of the response to flu-
voxamine treatment with contamination-related OCD
patients in a PET study in the context of a symptom-
provocation paradigm. This study reported that decreased
rCBF values in the OFC and increased rCBF values in
the posterior cingulate cortex predicted a better response
to treatment.
A few studies have reported that posterior brain regions
are associated with the response to SSRI treatment. In this
study, increased and decreased rCBF was found in the SSRIFigure 2 The image A was the most intensity projection image of the
was the three dimensional image of rendered with decreased rCBF focusesplus quetiapine group. The regions of decreased rCBF pri-
marily included the left inferior parietal lobule, left vermis
cerebelli and right occipital wedge leaf. The regions of in-
creased rCBF primarily included the left tonsil of the cere-
bellum, left globus pallidus, right thalamic lateral nucleus,
right lentiform nucleus, and right middle frontal gyrus. Ho
Pian et al. [22] reported that the pre-treatment cerebellar
and whole brain HMPAO uptake was higher in subjects
that responded to fluvoxamine treatment compared to
non-responders. Nabeyama et al. [23] reported that the
dysfunction of posterior brain regions, especially the cere-
bellum, is involved in the pathogenesis of OCD and that a
normalization of function can occur with an improvement
in OCD symptoms. Therefore, posterior brain regions such
as the cerebellum and occipital lobe might be associated
with the subsequent treatment response to selective sero-
tonin reuptake inhibitors (SSRI) in patients with OCD.
Several reports have suggested that the activities of fore-
brain and posterior brain regions such as the cerebellum
and occipital lobe might be involved in the pathophysi-
ology of OCD [3,12,23]. Our results completely support
this conclusion.decreased rCBF focuses in the patients with OCD. The image B
.
Figure 3 The image A was the most intensity projection image of the increased rCBF focuses in the patients with OCD. The image B
was the three dimensional image of rendered with increased rCBF focuses.
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rCBF in forebrain. SSRI plus quetiapine responders
had the reduced rCBF in cerebellum, occipital cortex
and parietal cortex and increased rCBF in forebrain,
which is correlated with the reduction of Y-BOCS scores.
SSRI plus qurtiapine responders may be a subgroup
representing a reduced capability for establishing neur-
onal connectivity compared to SSRI responders. Hendler
[20] argued that SSRI nonresponsive OCD patients might
lack the capability for cortical plasticity by SSRI due to
more cortical deficits. Thus these patients may require a
more complex modulation of fronto-thalamic-striatal
circuits for achieving clinical improvement. Quetiapine
augmentation maybe mediated by increasing rCBF in
cerebellum, occipital cortex and parietal cortex regions asTable 3 The coordinates and Z scores of abnormal rCBF in
before treatment
Hemisphere Brain region C
X
Decreased rCBF
left inferior parietal lobule −42
left Vermis cerebelli −6
right Occiput wedge leaf 6
Increased rCBF
left Tonsil of cerebellum −34
left Globus pallidus −22
right Thalamus lateral nucleus 22
right Lentiform nucleus 30
right Middle frontal gyrus 12
a Coordinates from the stereotaxic atlas of Talairach and Tournoux.
b Peak activation in a cluster of at least 50 voxels in which the difference survived areported in the patient with psychotic disorders [24,25].
However, this interpretation should be cautiously consid-
ered because non-responder patients receiving quetiapine
is lacked in our research.
The limitations of the present study include the fact
that the low spatial resolution of brain SPECT imaging
scintillation cameras (10 mm) limits the detection of ab-
normalities in small brain regions or the identification
of discrete brain abnormalities. In addition, the sample
size was small, and thus our results may be difficult to
generalize. We require a larger number of subjects to
analyze the results with reference to the heterogeneity
of OCD and to better investigate the correlations be-
tween changes in the rCBF and symptom improvement.
Furthermore, we failed to examine the non-responsiveSSRI plus quetiapine group and normal controls
oordinates(mm)a Z scoresb P value
Y Z
−52 46 6.98 0.000
−74 −32 6.91 0.000
−70 16 7.06 0.000
−58 −38 5.09 0.000
−12 4 4.75 0.000
−18 8 4.61 0.000
−20 8 6.67 0.000
52 16 4.41 0.000
threshold of P < 0.001 in a random-effects analysis.
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requiring a longer follow-up period may have a negative
effect on the patients’ compliance to the study protocol.
Conclusions
To our knowledge, there is few study investigating the
brain imaging findings associated with clinical remission
in OCD patients. We found that SSRI responders were
characterized by increased rCBF in forebrain regions, in-
cluding the frontal cortex, basal ganglia, thalamus and
cingulate gyrus. The SSRI plus quetiapine responders
were characterized by increased rCBF changes in the
forebrain regions along with decreased rCBF changes in
posterior brain regions, including the occipital lobe,
inferior parietal lobe and cerebella. Notwithstanding
the limitations mentioned above, before treatment the
changes in rCBF are associated with pharmacotherapy
and clinical improvement in OCD patients and may
be valuable in guiding the choice of clinical pharma-
cotherapy in OCD patients.
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